Please assess the completion status of the following clinical trial:

Trial Title: CPX-351 Real-World Effectiveness and Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years at the start of treatment of AML with Vyxeos liposomal~* Pathological diagnosis of t-AML or AML-MRC according to World Health Organization criteria (with at least 20% blasts in the peripheral blood or bone marrow)~* Patient has received at least one infusion of Vyxeos liposomal, prescribed as per the SmPC~* Patient signs an informed consent form or is included in accordance with an informed consent waiver~Exclusion Criteria:~* Treatment with Vyxeos liposomal as part of a clinical trial or managed access program~* Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood counts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPX-351 (Type: None): Adult patients with newly diagnosed, therapy related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who were treated in routine practice with Vyxeos liposomal in the UK.

Based on this trial design, predict the completion outcome and termination type (if applicable).